Clinical Trial Update: TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial investigating trastuzumab and pertuzumab for HER2-positive resectable esophageal cancer (esophageal adenocarcinoma) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Esophageal Cancer, Esophageal Adenocarcinoma | Phase 3 | Status: RECRUITING